Ab­b­Vie banks on sec­ond-gen TL1A pro­gram, li­cens­ing an­ti­body from Fu­ture­Gen

Ab­b­Vie is jump­ing in­to the TL1A space, ink­ing a new deal with a Bei­jing-based biotech.

The com­pa­ny said Thurs­day that it’s part­ner­ing with Fu­ture­Gen Bio­phar­ma­ceu­ti­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.